GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (HAM:MAH0) » Definitions » EV-to-FCF

Mereo BioPharma Group (HAM:MAH0) EV-to-FCF : -24.89 (As of Jun. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Mereo BioPharma Group EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mereo BioPharma Group's Enterprise Value is €494.36 Mil. Mereo BioPharma Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-19.86 Mil. Therefore, Mereo BioPharma Group's EV-to-FCF for today is -24.89.

The historical rank and industry rank for Mereo BioPharma Group's EV-to-FCF or its related term are showing as below:

HAM:MAH0' s EV-to-FCF Range Over the Past 10 Years
Min: -26.24   Med: -4.76   Max: 8.6
Current: -26.24

During the past 9 years, the highest EV-to-FCF of Mereo BioPharma Group was 8.60. The lowest was -26.24. And the median was -4.76.

HAM:MAH0's EV-to-FCF is ranked worse than
100% of 402 companies
in the Biotechnology industry
Industry Median: 5.935 vs HAM:MAH0: -26.24

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-23), Mereo BioPharma Group's stock price is €3.55. Mereo BioPharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.024. Therefore, Mereo BioPharma Group's PE Ratio for today is At Loss.


Mereo BioPharma Group EV-to-FCF Historical Data

The historical data trend for Mereo BioPharma Group's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group EV-to-FCF Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only - - -10.85 -0.82 -12.95

Mereo BioPharma Group Quarterly Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.85 - -0.82 - -12.95

Competitive Comparison of Mereo BioPharma Group's EV-to-FCF

For the Biotechnology subindustry, Mereo BioPharma Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's EV-to-FCF falls into.



Mereo BioPharma Group EV-to-FCF Calculation

Mereo BioPharma Group's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=494.360/-19.864
=-24.89

Mereo BioPharma Group's current Enterprise Value is €494.36 Mil.
Mereo BioPharma Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-19.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mereo BioPharma Group  (HAM:MAH0) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Mereo BioPharma Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.55/-0.024
=At Loss

Mereo BioPharma Group's share price for today is €3.55.
Mereo BioPharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.024.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Mereo BioPharma Group EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group (HAM:MAH0) Business Description

Comparable Companies
Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (HAM:MAH0) Headlines

No Headlines